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Abstract
OBJECTIVES: To estimate heroin overdose trends among insured individuals and characterize 
patients and healthcare utilization preceding overdose to inform scale-up of effective prevention 
and treatment.
STUDY DESIGN: Retrospective descriptive analysis.
METHODS: We analyzed 2010 to 2014 IBM MarketScan Databases and calculated annual heroin 
overdose rates. For a subset of patients, we describe their comorbidities, where they accessed 
health services, and select prescription histories prior to their first heroin overdose.
RESULTS: Heroin overdose rates were much lower, but increased faster, among the 
commercially insured compared with Medicaid enrollees from 2010 to 2014 (270.0% vs 94.3%). 
By 2012, rates among the commercially insured aged 15 to 24 years reached the overall rates in 
the Medicaid population. All patients had healthcare encounters in the 6 months prior to their first 
heroin overdose; two-thirds of commercially insured patients had outpatient visits, whereas two-
thirds of Medicaid patients had emergency department visits. One month prior to overdose, 24.5% 
of Medicaid and 8.6% of commercially insured patients had opioid prescriptions. Fewer Medicaid 
patients had buprenorphine prescriptions (17.8% vs 27.3%) despite similar rates of known 
substance-related disorders. A higher proportion of Medicaid patients had non-substance-related 
comorbidities.
CONCLUSIONS: Heroin overdose rates were persistently higher among the Medicaid 
population than the commercially insured, with the exception of those aged 15 to 24 years. Our 
findings on healthcare utilization, comorbidities, and where individuals access services could 
inform interventions at the point of care prior to a first heroin overdose. Outpatient settings are of 
particular importance for the growing cohort of young, commercially insured patients with opioid 
use disorders.
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America’s opioid epidemic continues to grow. The negative health outcomes and healthcare 
costs associated with the epidemic are well documented,1 with opioid overdose fatalities 
making up the most acute and reliable measure. In 2014, the CDC reported the highest 
number of opioid overdose fatalities (28,647) during any previous year on record,2 only to 
report that this unprecedented number was surpassed with 47,600 opioid overdose deaths by 
20l73
Although the rising number of annual opioid overdose deaths indicates that the opioid 
epidemic has not yet peaked, the relative contribution of different drug types to the epidemic 
is changing. In 2015, the CDC reported that the heroin-involved overdose mortality rate was 
increasing more than overdose deaths involving commonly prescribed opioids (20.6% vs 
2.5%).4 As heroin deaths approach the number of prescription opioid deaths, another 
challenge has emerged from illicitly manufactured fentanyl (IMF).5
The dynamic nature of the opioid overdose epidemic poses continuous challenges to 
prevention efforts.6 Despite the problem of polysubstance use among heroin users,7 
demographic changes in opioid use patterns are also well documented. Younger patients 
have higher prevalence of heroin use disorders,8 and national reports identify that the largest 
increases in percentage of individuals with heroin use disorder from 2010 to 2014 are among 
those aged 18 to 25 years.9 National death data similarly show high heroin overdose rates 
among younger age groups.3,4 Heroin is frequently adulterated with IMF, and deaths 
involving synthetic opioids, such as fentanyl, are also highest among younger age groups.3–5
These studies of recent trends in heroin use and mortality are critically important for 
identifying at-risk groups. However, they do not provide essential information on the 
underlying patterns in healthcare utilization preceding an overdose or prior prescription 
opioid use—an important concern given the association between opioid use disorders 
involving prescription opioids and heroin.7 For this study, we aimed to characterize trends in 
heroin overdoses treated in healthcare settings for an insured population and to describe 
healthcare encounters before the overdose, including diagnoses and use of prescription 
opioids, benzodiazepines, and buprenorphine. Patients treated for heroin overdose in 
healthcare settings include those who survive the overdose, as well as those for whom the 
overdose was fatal. We used longitudinal patient-level and payer-specific data to explore 
these characteristics and identify whether opportunities for preoverdose interventions exist, 
given that interventions are frequently initiated when an overdose occurs but there may be 
opportunities to intervene further upstream. These aspects provide insight into the diverging 
trajectory of the heroin epidemic, including patients’ risk profiles beyond substance use 
disorders, and may contribute to a more effective prevention strategy.
METHODS
Data Source
Data for Medicaid and commercially insured enrollees were analyzed separately for 2010 to 
2014. We analyzed administrative claims data from IBM MarketScan Research Databases, 
which are derived from a convenience sample of commercially insured and Medicaid 
enrollees. Approximately half of the US population is covered by employer-sponsored 
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commercial health plans,10 and the IBM MarketScan Commercial Databases capture data on 
more than a quarter of these individuals annually from every state in the United States. 
Approximately 20% of the US population is covered by Medicaid.11 The IBM MarketScan 
Multi-State Medicaid Databases are derived from 10 to 13 unidentified geographically 
dispersed states from each of the 4 Census regions, capturing both fee-for-service and 
managed care data. The numbers of enrollees in our sample for each study year are provided 
in Table 1. The IBM MarketScan Databases encompass the full continuum of healthcare, 
including inpatient, outpatient, and emergency department (ED) services, as well as 
prescriptions dispensed through retail pharmacies.
Of note, Medicaid and commercial health plans cover approximately half of all ED visits 
and admissions in the United States for heroin overdose (data not shown). Our analysis 
focuses on those who overdose on heroin and are insured, and we acknowledge that there 
maybe differences between them and those who are uninsured. Although insured individuals 
who overdose on heroin are not representative of all who overdose on heroin, they are most 
likely to be affected by reforms in clinical practice and insurance oversight.
Sample
IBM MarketScan provides access to data on enrollees who have prescription drug coverage. 
All analyses were restricted to enrollees aged 15 to 64 years, as there are few heroin 
overdoses in younger adolescents and children, and the number of enrollees 65 years or 
older drops off considerably as they transition to Medicare. When calculating annual rates, 
we included only individuals continuously enrolled throughout a given calendar year. For 
2014 Medicaid data, we included only individuals who were continuously enrolled in both 
2013 and 2014. This kept our sample consistent by reducing the impact of a large increase in 
MarketScan Medicaid enrollees in 2014 due in part to Medicaid expansion under the 
Affordable Care Act.
Measures and Analyses
Overdose rates.—Within each calendar year, we identified enrollees with at least 1 
inpatient, outpatient, or ED claim with an International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) diagnosis of 965.01 (poisoning by heroin) or 
E850.0 (accidental poisoning by heroin). We then stratified our study population by gender 
and age categories to calculate heroin overdose rates by demographic characteristics. 
Distinct from the diagnostic codes for heroin overdose, we also calculated opioid (other than 
heroin) overdose rates (eAppendix [available at ajmc.com]) for each year to compare with 
heroin overdose trends. In 2017, Green et al reported that ICD-9-CM codes for opioid-
related poisoning had a very high predictive value, suggesting that they can be used to 
monitor overdose rates.12
Healthcare utilization, prescriptions, and diagnoses prior to overdose.—We 
next conducted additional analyses on a subset of patients experiencing heroin overdose. We 
examined diagnoses, healthcare utilization, and select controlled substance prescriptions 
among patients experiencing heroin overdose who had 18 months of continuous enrollment 
prior to their first heroin overdose in the study period. Eighteen months provided a 
Bohm et al. Page 3
Am J Manag Care. Author manuscript; available in PMC 2020 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
retrospective period with no heroin overdose, such that the index heroin overdose event we 
examined was regarded as the “first heroin overdose” for our study purposes. We had access 
to data from 2009 but not 2008, so we excluded patients with a heroin overdose occurring in 
the first 6 months of 2010.
We then assessed the proportion of patients with at least 1 ED visit, inpatient admission, or 
outpatient visit in the 6 months prior to the impending overdose to highlight opportunities 
for screening, intervention, or referral during such encounters. Encounters in the 14 days 
prior to the overdose were not considered to avoid capturing claims that may have been 
related to the first heroin overdose and to focus on missed opportunities that would have 
allowed a reasonable amount of time for intervention prior to the index event. We also 
determined the proportion of patients filling a prescription for buprenorphine indicated for 
the treatment of opioid use disorder anytime up to 3 days before the overdose. We next 
determined the proportion of patients with prescriptions for opioids in the 6 months, 3 
months, and 1 month prior to the overdose, and repeated this for benzodiazepines. Lastly, we 
identified common diagnoses in the 6 months prior to the heroin overdose using categories 
from the Healthcare Cost and Utilization Project Clinical Classifications Software for 
ICD-9-CM.13 Diagnoses included those received in the course of inpatient admissions or 
during outpatient or ED visits.
RESULTS
Overdose Rates
Heroin overdose rates were lower than opioid (other than heroin) overdose rates but 
increased over time. We observed much higher heroin overdose rates among the Medicaid 
population compared with the commercially insured population, but rates increased faster 
among the commercially insured from 2010 to 2014 (Table 1). Heroin overdose rates 
increased 270.0% among the commercially insured—from 1.9 to 7.1 per 100,000 enrollees
—during the study period. Among the Medicaid population, these rates increased 94.3% 
during the same time period—from 15.7 to 30.5 per 100,000 enrollees. In contrast, opioid 
(other than heroin) overdose rates remained fairly stable, although much higher than heroin 
overdose rates.
Heroin overdose rates were consistently higher among male than female enrollees, 
irrespective of health insurance type. In 2014, the rates of heroin overdose among male and 
female enrollees were 10.5 and 4.1 per 100,000 commercial enrollees, respectively, and 34.9 
and 28.0 per 100,000 Medicaid enrollees, respectively. The highest heroin overdose rates 
among the commercially insured were in the youngest age group—those aged 15 to 24 years 
(30.3 per 100,000 in 2014)—whereas among the Medicaid population, this age group had 
the lowest rates (14.0 per 100,000 in 2014). In 2012, heroin overdose rates among the 
commercially insured aged 15 to 24 years were similar to the overall rates of heroin 
overdose in the Medicaid population. Among the commercially insured, heroin overdose 
rates declined as age category increased, whereas rates remained steady among Medicaid 
enrollees aged 35 to 64 years.
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Healthcare Utilization, Prescriptions, and Diagnoses Prior to Overdose
Nearly all enrollees with heroin overdose had at least 1 healthcare encounter in the 6 months 
prior to their first overdose, including approximately 1 in 4 having an inpatient admission 
(Table 213). A higher proportion of commercially insured (64.7%) than Medicaid (36.6%) 
patients had outpatient visits, whereas the opposite was true for ED visits (35.5% vs 62.1%). 
A consistently higher proportion of Medicaid patients were prescribed opioids prior to their 
heroin overdose. For instance, within 1 month of the overdose, 24.5% of Medicaid patients 
and 8.6% of commercially insured patients had prescriptions for opioids, which is a nearly 
3-fold difference. Additionally, a higher proportion of Medicaid patients were prescribed 
benzodiazepines. Specifically, 29.0% of Medicaid and 14.5% of commercially insured 
patients received benzodiazepine prescriptions within 1 month of the overdose. More 
enrollees on Medicaid (14.5% vs 3.9%) were also prescribed both benzodiazepines and 
opioids within 1 month of overdose. Prescriptions for buprenorphine indicated for the 
treatment of opioid use disorder were prescribed less frequently for Medicaid patients than 
commercially insured patients (17.8% vs 27.3%) preceding the overdose.
Table 213 lists the categories of diagnoses received by patients in the 6 months prior to their 
heroin overdose. Similar proportions of both Medicaid and commercially insured 
populations were diagnosed with substance-related disorders other than alcohol and tobacco 
(approximately 49%) (see eAppendix for codes for opioid overdose and substance-related 
disorders) and with alcohol-related disorders specifically (approximately 14%). However, 
for all other diagnoses, the proportion receiving the diagnosis was higher among the 
Medicaid than commercially insured patients. Notably, there were approximately 3-fold 
higher proportions of Medicaid patients than commercially insured patients with diagnoses 
of nonspecific chest pain, other nervous system disorders, and hepatitis (all forms of viral 
hepatitis and chronic hepatitis associated with liver disease and cirrhosis).
DISCUSSION
We found increasing trends in heroin overdose rates that reflect previously reported 
increases in heroin use and heroin-related overdose deaths.7,14 During the study period of 
2010 to 2014, opioid (other than heroin) overdose rates remained stable, whereas heroin 
overdose rates increased steadily among most demographic groups year to year; however, 
we acknowledge that these increases were relative to initially small heroin overdose rates. 
Our findings that men, young adults, and Medicaid enrollees had the highest rates of heroin 
overdose are consistent with prior research.3,7–9 Our inclusion of nonfatal overdoses and 
demographic stratifications by payer type provide additional insight into the trajectory of the 
heroin epidemic. Among the commercially insured population, the highest heroin overdose 
rates were among those aged 15 to 24 years. During 2012 to 2014, this is the only age group 
among the commercially insured whose rates were similar to those of their Medicaid 
counterparts and the overall rates among the Medicaid population. This may represent an 
emerging cohort of commercially insured individuals with high prevalence of heroin use. In 
comparison, the same age group with Medicaid insurance had the lowest heroin overdose 
rates among all Medicaid age groups in every year. All other Medicaid age groups (ages 25–
64 years) had consistently high heroin overdose rates, signaling persistent substance use 
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disorder prevalence.15,16 Although rates of heroin overdose are currently lower among the 
commercially insured, their numbers may account for a substantial burden from heroin 
overdose given that more than half of the US population is covered by employer-sponsored 
commercial health plans.10
Healthcare utilization patterns prior to heroin overdoses indicate that nearly all enrollees had 
at least 1 healthcare encounter (all diagnoses) in the 6 months prior to their first overdose; 
the majority of commercially insured patients (64.7%) received healthcare through 
outpatient visits, whereas most Medicaid patients (62.1%) accessed the ED. This is 
consistent with what we know about insurance type and healthcare access in general.17 
Healthcare utilization patterns prior to heroin overdoses confirm that these high-risk insured 
patients are not “lost to follow-up” or absent from healthcare settings. This emphasizes the 
importance of the healthcare system’s role in preventing overdoses by offering brief 
interventions, coordinating medical and mental health services, and linking patients to 
appropriate care, such as substance use disorder treatment. Differences in patient healthcare 
utilization patterns based on payer type have implications for prevention efforts aimed at 
those at risk for heroin overdose. This knowledge allows for the development of targeted 
evidence-based strategies specific to the healthcare settings where these populations are 
most likely to access care. Although EDs are frequent sites of interventions related to 
substance use disorders, outpatient settings could be explored to better target young, 
commercially insured patients at risk for overdose.
Prescribing patterns prior to overdose show that opioid prescribing was higher among the 
Medicaid population, which could be related to high rates of comorbidities known to cause 
pain. A greater proportion of Medicaid patients had diagnoses of mood, anxiety, or nervous 
system disorders; connective tissue disease; joint disorders; back problems; lower 
respiratory diseases; and hepatitis. High prevalence of comorbidities in our population is 
consistent with Medicaid populations in general, but nonetheless underscores the importance 
of screening to ensure that all underlying conditions are appropriately treated. Given that the 
highest heroin overdose rate in the commercially insured population was among those aged 
15 to 24 years, the finding of a relatively lower proportion of commercially insured with 
opioid prescriptions could be due to adolescents and young adults being more likely than 
other age groups to obtain prescription opioids from a friend or relative.18 Another 
explanation could relate to individuals now more frequently reporting heroin as their opioid 
of initiation.19 Additionally a higher proportion of the Medicaid population received both 
opioid and benzodiazepine prescriptions prior to heroin overdose. We found higher 
benzodiazepine prescribing than opioid prescribing, which is the opposite of what is true for 
opioid and benzodiazepine prescribing prevalence in the general population20,21 and likely 
reflects more mental health conditions in our study population.
The association between poorer overall health and higher opioid utilization emphasizes the 
need for clinicians to coordinate care and adopt evidence-based prescribing practices. 
Judicious opioid prescribing, in accordance with the CDC Guideline for Prescribing Opioids 
for Chronic Pain,22 would be warranted among our high-risk study group, many of whom 
had documented histories of substance use disorders. In addition to monitoring illicit drug 
use, clinicians can use prescription drug monitoring data to check if patients have 
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overlapping opioid and/or benzodiazepine prescriptions. The concurrent use of opioids and 
benzodiazepines should be avoided per the FDA’s new warnings.22–25
Although nearly half of all patients who overdosed on heroin in this study were previously 
diagnosed with substance-related disorders, relatively few had prescriptions for 
buprenorphine, 1 of the 3 medications used in medication-assisted treatment (MAT) for 
opioid use disorder. These low proportions, especially among Medicaid patients, signal 
opportunities for improving access to this therapy and potentially preventing overdose. 
Research has shown that MAT can be effective in the treatment of opioid use disorder and 
can reduce healthcare utilization.26
Screening and treatment for hepatitis C and HIV is of particular importance for all patients 
using heroin. Many individuals who report heroin use inject the drug,27 which carries 
considerable risk for the transmission of bloodborne diseases through needle sharing. In 
accordance with recommendations from the CDC,28 those who inject drugs should be tested 
for HIV and hepatitis and vaccinated against viral hepatitis B if not immune. Access to 
comprehensive syringe services programs is also crucial for individuals who use heroin to 
mitigate risk of overdose and of bloodborne pathogen transmission. Although a nearly 3-fold 
greater proportion of the Medicaid population had diagnosed hepatitis (16.8% vs 6.1%), 
many hepatitis B and C infections remain undiagnosed in the United States. The emerging 
cohort of young, commercially insured patients with high heroin overdose rates warrants 
further investigation to determine whether they have hepatitis or other infectious disease 
rates more similar to the Medicaid population.
Limitations
There are limitations to consider with regard to our results. First, the study may have yielded 
different results if the analyses were not restricted to the continuously enrolled population. 
For example, “churning” is common among Medicaid enrollees, whereby individuals 
fluctuate between states of eligibility and ineligibility, resulting in sporadic coverage.29 It is 
known that continuously enrolled patients are more likely to have chronic conditions.30–32 A 
second limitation is the potential effect resulting from Medicaid expansion under the 
Affordable Care Act. In 2013, rates of substance use disorders among currently uninsured 
Medicaid-eligible individuals were found to be slightly higher than the rates among current 
Medicaid enrollees.33 Because we excluded newly eligible Medicaid enrollees, the rates of 
heroin overdose in our study are likely conservative. A third limitation is that variability in 
coding practices means that the opioid overdoses we identified could potentially include 
some heroin overdoses. However, Green et al found high positive predictive values for 
opioid and heroin overdose codes.12 Fourth, results are not nationally representative and 
should be interpreted with caution. Finally, due to the nature of claims data, heroin 
overdoses that did not involve transport to a medical facility, including fatal overdoses, may 
not have been captured.
CONCLUSIONS
Medicaid and private insurance pay for nearly half of heroin overdoses in the United States. 
Healthcare encounters for heroin overdose increased significantly from 2010 to 2014 for 
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these groups. Rates among Medicaid enrollees were higher, yet rates increased faster among 
the commercially insured. Healthcare utilization patterns among insured patients who 
overdose on heroin suggest that opportunities exist for interventions at the point of care prior 
to the first overdose. We noted differences in where patients accessed care by insurance 
coverage type, which can inform targeted and tailored prevention efforts. Outpatient settings 
are of particular importance for the emerging cohort of young, commercially insured 
patients aged 15 to 24 years with opioid use disorder. Moreover, many patients in our study 
had multiple comorbidities in addition to known substance use disorders. This emphasizes 
the importance of coordinated care for all underlying conditions, judicious prescribing 
practices in accordance with the CDC’s guideline, referral to or induction on MAT, 
provision of naloxone, and screening and referral to treatment and prevention resources for 
viral hepatitis and HIV. ■
Source of Funding:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit 
sectors. The findings and conclusions in this article are those of the authors and do not necessarily represent the 
official position of the CDC.
eAppendix.
ICD-9-CM Codes for Opioid Overdose and Substance-Related Disorders per Healthcare 
Cost and Utilization Project (HCUP) Clinical Classifications Software (CCS) for ICD-9-
CM. Agency for Healthcare Research and Quality, Rockville, MD.
Opioid Overdose:
96502 96509 9658 8501 E8501 E8502 E8508
Substance-related Disorders:
2920 29211 29212 2922 29281 29282 29283 29284 29285 29289 2929 30400 30401 30402 
30403 30410 30411 30412 30413 30420 30421 30422 30423 30430 30431 30432 30433 
30440 30441 30442 30443 30450 30451 30452 30453 30460 30461 30462 30463 30470 
30471 30472 30473 30480 30481 30482 30483 30490 30491 30492 30493 30520 30521 
30522 30523 30530 30531 30532 30533 30540 30541 30542 30543 30550 30551 30552 
30553 30560 30561 30562 30563 30570 30571 30572 30573 30580 30581 30582 30583 
30590 30591 30592 30593 64830 64831 64832 64833 64834 65550 65551 65553 76072 
76073 76075 7795 96500 96501 96502 96509 V6542
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TAKEAWAY POINTS
Healthcare utilization patterns among insured patients who experience heroin overdose 
highlight opportunities for interventions before the first overdose, noting differences in 
patient characteristics and healthcare access points by insurance type.
• Medicaid and commercial insurance pay for approximately half of heroin 
overdoses, and nearly all insured patients access healthcare services in the 6 
months prior to overdose.
• Outpatient interventions are important for the emerging cohort of young, 
commercially insured patients with opioid use disorder.
• Many insured patients who experience heroin overdose have multiple 
comorbidities, emphasizing the importance of coordinated care, including 
mental health care, judicious opioid and benzodiazepine prescribing, 
medication-assisted treatment, provision of naloxone, and prevention of 
infectious disease transmission.
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TABLE 2.
Health Services, Prescriptions, and Diagnoses Prior to First Heroin Overdose by Insurance Coverage Type
Commercial
Insurance
(2010–2014)
Medicaid
(2010–2014)
n % n %
Patients continuously enrolled 18 months prior to heroin overdose 4623 100 1114 100
Health Services 6 Months Prior to Heroin Overdosea
Any outpatient visit, ED visit, or inpatient admission 4620 99.9 1101 98.8
≥1 outpatient visit 2991 64.7 408 36.6
≥1 ED visit 1640 35.5 692 62.1
≥1 inpatient admission 1235 26.7 306 27.5
Prescriptions Prior to Heroin Overdose
Opioids
 ≥1 opioid prescription 6 months prior to overdose 1139 24.6 570 51.2
 ≥1 opioid prescription 3 months prior to overdose 760 16.4 434 39.0
 ≥1 opioid prescription 1 month prior to overdose 396 8.6 273 24.5
Benzodiazepines
 ≥1 benzodiazepine prescription 6 months prior to overdose 1098 23.8 447 40.1
 ≥1 benzodiazepine prescription 3 months prior to overdose 901 19.5 393 35.3
 ≥1 benzodiazepine prescription 1 month prior to overdose 671 14.5 323 29.0
Opioid and benzodiazepine prescription 1 month prior to overdose 178 3.9 161 14.5
Medication-Assisted Treatment
Buprenorphine any time between 18 months and 3 days prior to heroin overdose 1263 27.3 198 17.8
Frequent Diagnosesb 6 Months Prior to Heroin Overdosea
Abdominal pain 423 9.1 227 20.4
Alcohol-related disorders 618 13.4 165 14.8
Anxiety disorders 1215 26.3 404 36.3
Headache 333 7.2 168 15.1
Hepatitis 281 6.1 187 16.8
Lower respiratory disease 478 10.3 262 23.5
Mood disorders 1391 30.1 491 44.1
Nonspecific chest pain 286 6.2 181 16.2
Other connective tissue disease 644 13.9 285 25.6
Other injuries and conditions due to external causes 437 9.5 227 20.4
Other nervous system disorders 407 8.8 288 25.9
Other nontraumatic joint disorders 461 10.0 241 21.6
Spondylosis; intervertebral disc disorders; other back problems 741 16.0 334 30.0
Substance-related disorders (other than alcohol and tobacco] 2256 48.8 552 49.6
ED indicates emergency department.
a
Health services and diagnoses do not include those received during the 2 weeks prior to overdose.
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b
Diagnostic categories are from Clinical Classifications Software for International Classification of Diseases, Ninth Revision, Clinical 
Modification,13 See eAppendix for codes for opioid overdose and substance-related disorders.
Source: IBM MarketScan Commercial and Multi-State Medicaid Databases—United States, 2010–2014.
Am J Manag Care. Author manuscript; available in PMC 2020 July 01.
